Also trades as: HLS.TO (TSX) · $vol 0M
HLTRF OTC
HLS Therapeutics Inc.
1W: -1.4%
1M: +4.2%
3M: -8.3%
YTD: -19.8%
1Y: -27.6%
3Y: -37.8%
5Y: -80.8%
$2.75
-0.04 (-1.43%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$56M
-0.3% ▼
5Y CAGR: +0.1%
Gross Profit
$24M
-49.6% ▼
5Y CAGR: -14.5%
Operating Income
-$4M
+45.6% ▲
Net Income
-$13M
+35.7% ▲
EPS (Diluted)
$-0.40
+35.5% ▲
EBITDA
$18M
+4.7% ▲
5Y CAGR: -5.9%
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $60M | $61M | $63M | $57M | $56M |
| YoY Growth | +7.0% | +2.4% | +2.6% | -10.2% | -0.3% |
| Cost of Revenue | $4M | $5M | $8M | $9M | $32M |
| Gross Profit | $56M | $56M | $55M | $48M | $24M |
| Gross Margin | 93.4% | 91.9% | 87.9% | 84.1% | 42.5% |
| R&D Expenses | $0 | $0 | $0 | $0 | $0 |
| SG&A Expenses | $32M | $36M | $28M | $27M | $22M |
| Operating Expenses | $62M | $70M | $55M | $55M | $28M |
| Operating Income | -$6M | -$13M | -$10M | -$8M | -$4M |
| Operating Margin | -10.5% | -21.9% | -16.4% | -13.6% | -7.4% |
| Interest Expense | $7M | $7M | $9M | $10M | $7M |
| Income Before Tax | -$12M | -$24M | -$28M | -$16M | -$13M |
| Tax Expense | $1M | -$124K | -$272K | $4M | -$453K |
| Net Income | -$13M | -$24M | -$28M | -$20M | -$13M |
| Net Margin | -21.9% | -38.4% | -43.6% | -34.7% | -22.4% |
| EPS (Diluted) | $-0.41 | $-0.73 | $-0.85 | $-0.62 | $-0.40 |
| EBITDA | $25M | $17M | $13M | $17M | $18M |
| Shares Outstanding | 32M | 32M | 32M | 32M | 32M |